Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 505 Results

Page 1 of 5112 3 4 5...10 20 30...»Last »

September 3, 2026

DBV Technologies to Participate in Upcoming September Investor Conferences

September 2, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

July 30, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

July 17, 2026

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

July 16, 2026

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

July 16, 2026

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

July 14, 2026

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

July 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

June 29, 2026

DBV Technologies Provides BLA Submission Update for the VIASKIN^® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

June 23, 2026

DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

Page 1 of 5112 3 4 5...10 20 30...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top